ID   TCAM1_HUMAN             Reviewed;         712 AA.
AC   Q8IUC6; B3Y691; O75532; Q86XP8; Q96GA0;
DT   05-FEB-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   28-JUN-2023, entry version 173.
DE   RecName: Full=TIR domain-containing adapter molecule 1;
DE            Short=TICAM-1;
DE   AltName: Full=Proline-rich, vinculin and TIR domain-containing protein B;
DE   AltName: Full=Putative NF-kappa-B-activating protein 502H;
DE   AltName: Full=Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta;
DE            Short=MyD88-3;
DE            Short=TIR domain-containing adapter protein inducing IFN-beta;
GN   Name=TICAM1; Synonyms=PRVTIRB, TRIF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, DOMAIN, AND
RP   INTERACTION WITH IRF3; TLR2 AND TLR3.
RX   PubMed=12471095; DOI=10.4049/jimmunol.169.12.6668;
RA   Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K.,
RA   Akira S.;
RT   "A novel Toll/IL-1 receptor domain-containing adapter that preferentially
RT   activates the IFN-beta promoter in the Toll-like receptor signaling.";
RL   J. Immunol. 169:6668-6672(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH TLR3, SUBUNIT,
RP   TISSUE SPECIFICITY, DOMAIN, AND MUTAGENESIS OF PRO-434.
RC   TISSUE=Lung;
RX   PubMed=12539043; DOI=10.1038/ni886;
RA   Oshiumi H., Matsumoto M., Funami K., Akazawa T., Seya T.;
RT   "TICAM-1, an adapter molecule that participates in Toll-like receptor 3
RT   mediated interferon-beta induction.";
RL   Nat. Immunol. 4:161-167(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=18810425; DOI=10.1007/s00251-008-0332-0;
RA   Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T., Kimura A.;
RT   "Natural selection in the TLR-related genes in the course of primate
RT   evolution.";
RL   Immunogenetics 60:727-735(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=12761501; DOI=10.1038/sj.onc.1206406;
RA   Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O., Nagano Y.,
RA   Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H., Sugano S.;
RT   "Large-scale identification and characterization of human genes that
RT   activate NF-kappaB and MAPK signaling pathways.";
RL   Oncogene 22:3307-3318(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 137-712.
RA   Begum N.A.;
RT   "PRVTIRB is a differentially expressed gene.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 297-712.
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   INTERACTION WITH TICAM2.
RX   PubMed=12721283; DOI=10.1074/jbc.m303451200;
RA   Bin L.-H., Xu L.-G., Shu H.-B.;
RT   "TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter
RT   protein involved in TIR signaling.";
RL   J. Biol. Chem. 278:24526-24532(2003).
RN   [9]
RP   INTERACTION WITH TRAF6 AND TBK1, PHOSPHORYLATION BY TBK1, MOTIF, AND
RP   MUTAGENESIS OF GLU-88; GLU-252 AND GLU-303.
RX   PubMed=14530355; DOI=10.4049/jimmunol.171.8.4304;
RA   Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K.,
RA   Akira S.;
RT   "Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF)
RT   associates with TNF receptor-associated factor 6 and TANK-binding kinase 1,
RT   and activates two distinct transcription factors, NF-kappa B and IFN-
RT   regulatory factor-3, in the Toll-like receptor signaling.";
RL   J. Immunol. 171:4304-4310(2003).
RN   [10]
RP   INTERACTION WITH PIAS4.
RX   PubMed=15251447; DOI=10.1016/j.febslet.2004.05.081;
RA   Zhang J., Xu L.G., Han K.J., Wei X., Shu H.B.;
RT   "PIASy represses TRIF-induced ISRE and NF-kappaB activation but not
RT   apoptosis.";
RL   FEBS Lett. 570:97-101(2004).
RN   [11]
RP   FUNCTION, INTERACTION WITH IKBKB; IKBKE; IRF3; IRF7; TBK1 AND TRAF6, AND
RP   DOMAIN.
RX   PubMed=14739303; DOI=10.1074/jbc.m311629200;
RA   Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.;
RT   "Mechanisms of the TRIF-induced interferon-stimulated response element and
RT   NF-kappaB activation and apoptosis pathways.";
RL   J. Biol. Chem. 279:15652-15661(2004).
RN   [12]
RP   INTERACTION WITH TRAF6, AND MUTAGENESIS OF GLU-252 AND GLU-493.
RX   PubMed=14982987; DOI=10.1073/pnas.0308496101;
RA   Jiang Z., Mak T.W., Sen G., Li X.;
RT   "Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at
RT   Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3533-3538(2004).
RN   [13]
RP   INTERACTION WITH AZI2.
RX   PubMed=15611223; DOI=10.4049/jimmunol.174.1.27;
RA   Sasai M., Oshiumi H., Matsumoto M., Inoue N., Fujita F., Nakanishi M.,
RA   Seya T.;
RT   "NF-kappaB-activating kinase-associated protein 1 participates in
RT   TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN
RT   regulatory factor 3 activation.";
RL   J. Immunol. 174:27-30(2005).
RN   [14]
RP   INTERACTION WITH HCV NS3/4A PROTEASE (MICROBIAL INFECTION), MUTAGENESIS OF
RP   CYS-372, AND PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION).
RX   PubMed=15710891; DOI=10.1073/pnas.0408824102;
RA   Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C., Ikeda M., Ray S.C.,
RA   Gale M. Jr., Lemon S.M.;
RT   "Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of
RT   the Toll-like receptor 3 adaptor protein TRIF.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:2992-2997(2005).
RN   [15]
RP   INTERACTION WITH SARM1.
RX   PubMed=16964262; DOI=10.1038/ni1382;
RA   Carty M., Goodbody R., Schroeder M., Stack J., Moynagh P.N., Bowie A.G.;
RT   "The human adaptor SARM negatively regulates adaptor protein TRIF-dependent
RT   Toll-like receptor signaling.";
RL   Nat. Immunol. 7:1074-1081(2006).
RN   [16]
RP   REVIEW.
RX   PubMed=17457343; DOI=10.1038/nri2079;
RA   O'Neill L.A., Bowie A.G.;
RT   "The family of five: TIR-domain-containing adaptors in Toll-like receptor
RT   signalling.";
RL   Nat. Rev. Immunol. 7:353-364(2007).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH TLR5.
RX   PubMed=20855887; DOI=10.1074/jbc.m110.158394;
RA   Choi Y.J., Im E., Chung H.K., Pothoulakis C., Rhee S.H.;
RT   "TRIF mediates Toll-like receptor 5-induced signaling in intestinal
RT   epithelial cells.";
RL   J. Biol. Chem. 285:37570-37578(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH UBQLN1.
RX   PubMed=21695056; DOI=10.1371/journal.pone.0021153;
RA   Biswas N., Liu S., Ronni T., Aussenberg S.E., Liu W., Fujita T., Wang T.;
RT   "The ubiquitin-like protein PLIC-1 or ubiquilin 1 inhibits TLR3-Trif
RT   signaling.";
RL   PLoS ONE 6:E21153-E21153(2011).
RN   [20]
RP   CLEAVAGE BY HAV PROTEIN 3CD (MICROBIAL INFECTION), CLEAVAGE SITES, AND
RP   MUTAGENESIS OF GLN-190 AND GLN-554.
RX   PubMed=21931545; DOI=10.1371/journal.ppat.1002169;
RA   Qu L., Feng Z., Yamane D., Liang Y., Lanford R.E., Li K., Lemon S.M.;
RT   "Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A
RT   virus protease-polymerase processing intermediate, 3CD.";
RL   PLoS Pathog. 7:E1002169-E1002169(2011).
RN   [21]
RP   PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION), MUTAGENESIS OF GLN-653;
RP   GLN-659; GLN-672 AND GLN-702, AND INTERACTION WITH CVB3 PROTEASE 3C.
RX   PubMed=21436888; DOI=10.1371/journal.ppat.1001311;
RA   Mukherjee A., Morosky S.A., Delorme-Axford E., Dybdahl-Sissoko N.,
RA   Oberste M.S., Wang T., Coyne C.B.;
RT   "The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host
RT   type I interferon and apoptotic signaling.";
RL   PLoS Pathog. 7:E1001311-E1001311(2011).
RN   [22]
RP   INTERACTION WITH TRIM56.
RX   PubMed=22948160; DOI=10.1074/jbc.m112.397075;
RA   Shen Y., Li N.L., Wang J., Liu B., Lester S., Li K.;
RT   "TRIM56 is an essential component of the TLR3 antiviral signaling
RT   pathway.";
RL   J. Biol. Chem. 287:36404-36413(2012).
RN   [23]
RP   UBIQUITINATION BY TRIM38, AND MUTAGENESIS OF ASP-281 AND ASP-289.
RX   PubMed=23056470; DOI=10.1371/journal.pone.0046825;
RA   Xue Q., Zhou Z., Lei X., Liu X., He B., Wang J., Hung T.;
RT   "TRIM38 negatively regulates TLR3-mediated IFN-beta signaling by targeting
RT   TRIF for degradation.";
RL   PLoS ONE 7:E46825-E46825(2012).
RN   [24]
RP   PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION).
RX   PubMed=24672048; DOI=10.1128/jvi.03138-13;
RA   Xiang Z., Li L., Lei X., Zhou H., Zhou Z., He B., Wang J.;
RT   "Enterovirus 68 3C protease cleaves TRIF to attenuate antiviral responses
RT   mediated by Toll-like receptor 3.";
RL   J. Virol. 88:6650-6659(2014).
RN   [25]
RP   INTERACTION WITH TLR3; TICAM2; RIPK1; TRAF6 AND TBK1.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [26]
RP   FUNCTION, DOMAIN, INTERACTION WITH IRF3, PHOSPHORYLATION AT SER-210, AND
RP   MUTAGENESIS OF 210-SER--THR-214.
RX   PubMed=25636800; DOI=10.1126/science.aaa2630;
RA   Liu S., Cai X., Wu J., Cong Q., Chen X., Li T., Du F., Ren J., Wu Y.T.,
RA   Grishin N.V., Chen Z.J.;
RT   "Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF
RT   induces IRF3 activation.";
RL   Science 347:AAA2630-AAA2630(2015).
RN   [27]
RP   INTERACTION WITH SENECA VALLEY VIRUS PROTEASE 3C (MICROBIAL INFECTION),
RP   PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION), AND MUTAGENESIS OF GLN-159 AND
RP   GLN-190.
RX   PubMed=28566380; DOI=10.1128/jvi.00823-17;
RA   Qian S., Fan W., Liu T., Wu M., Zhang H., Cui X., Zhou Y., Hu J., Wei S.,
RA   Chen H., Li X., Qian P.;
RT   "Seneca Valley virus suppresses host type I interferon production by
RT   targeting adaptor proteins MAVS, TRIF, and TANK for cleavage.";
RL   J. Virol. 91:0-0(2017).
RN   [28]
RP   FUNCTION, INTERACTION WITH TRIM8, AND UBIQUITINATION BY TRIM8.
RX   PubMed=28747347; DOI=10.4049/jimmunol.1601647;
RA   Ye W., Hu M.M., Lei C.Q., Zhou Q., Lin H., Sun M.S., Shu H.B.;
RT   "TRIM8 Negatively Regulates TLR3/4-Mediated Innate Immune Response by
RT   Blocking TRIF-TBK1 Interaction.";
RL   J. Immunol. 199:1856-1864(2017).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 1-153, AND TRIF-NTD REGION.
RX   PubMed=24311583; DOI=10.1107/s0907444913022385;
RA   Ullah M.O., Ve T., Mangan M., Alaidarous M., Sweet M.J., Mansell A.,
RA   Kobe B.;
RT   "The TLR signalling adaptor TRIF/TICAM-1 has an N-terminal helical domain
RT   with structural similarity to IFIT proteins.";
RL   Acta Crystallogr. D 69:2420-2430(2013).
RN   [30] {ECO:0007744|PDB:5JEL}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 199-219 IN COMPLEX WITH IRF3,
RP   INTERACTION WITH IRF3, PHOSPHORYLATION AT SER-210, AND MUTAGENESIS OF
RP   SER-202 AND SER-210.
RX   PubMed=27302953; DOI=10.1073/pnas.1603269113;
RA   Zhao B., Shu C., Gao X., Sankaran B., Du F., Shelton C.L., Herr A.B.,
RA   Ji J.Y., Li P.;
RT   "Structural basis for concerted recruitment and activation of IRF-3 by
RT   innate immune adaptor proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:E3403-E3412(2016).
RN   [31]
RP   VARIANT [LARGE SCALE ANALYSIS] ILE-46.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [32]
RP   VARIANT IIAE6 LEU-186.
RX   PubMed=22105173; DOI=10.1172/jci59259;
RA   Sancho-Shimizu V., Perez de Diego R., Lorenzo L., Halwani R., Alangari A.,
RA   Israelsson E., Fabrega S., Cardon A., Maluenda J., Tatematsu M.,
RA   Mahvelati F., Herman M., Ciancanelli M., Guo Y., AlSum Z., Alkhamis N.,
RA   Al-Makadma A.S., Ghadiri A., Boucherit S., Plancoulaine S., Picard C.,
RA   Rozenberg F., Tardieu M., Lebon P., Jouanguy E., Rezaei N., Seya T.,
RA   Matsumoto M., Chaussabel D., Puel A., Zhang S.Y., Abel L., Al-Muhsen S.,
RA   Casanova J.L.;
RT   "Herpes simplex encephalitis in children with autosomal recessive and
RT   dominant TRIF deficiency.";
RL   J. Clin. Invest. 121:4889-4902(2011).
RN   [33]
RP   VARIANTS ILE-4; CYS-60; GLN-71; MET-80; THR-111; ARG-141 DEL; MET-157;
RP   LEU-186; LEU-302; ILE-377; PRO-386; LYS-392; ASN-465; ASN-557; LEU-595;
RP   TRP-598 AND ARG-702, AND CHARACTERIZATION OF VARIANTS ILE-4; CYS-60;
RP   GLN-71; MET-80; THR-111; ARG-141 DEL; MET-157; LEU-186; LEU-302; ILE-377;
RP   PRO-386; LYS-392; ASN-465; ASN-557; LEU-595; TRP-598 AND ARG-702.
RX   PubMed=32972995; DOI=10.1126/science.abd4570;
RG   COVID-STORM Clinicians;
RG   COVID Clinicians;
RG   Imagine COVID Group;
RG   French COVID Cohort Study Group;
RG   CoV-Contact Cohort;
RG   Amsterdam UMC Covid-19 Biobank;
RG   COVID Human Genetic Effort;
RG   NIAID-USUHS/TAGC COVID Immunity Group;
RA   Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J.,
RA   Ogishi M., Sabli I.K.D., Hodeib S., Korol C., Rosain J., Bilguvar K.,
RA   Ye J., Bolze A., Bigio B., Yang R., Arias A.A., Zhou Q., Zhang Y.,
RA   Onodi F., Korniotis S., Karpf L., Philippot Q., Chbihi M., Bonnet-Madin L.,
RA   Dorgham K., Smith N., Schneider W.M., Razooky B.S., Hoffmann H.H.,
RA   Michailidis E., Moens L., Han J.E., Lorenzo L., Bizien L., Meade P.,
RA   Neehus A.L., Ugurbil A.C., Corneau A., Kerner G., Zhang P., Rapaport F.,
RA   Seeleuthner Y., Manry J., Masson C., Schmitt Y., Schlueter A., Le Voyer T.,
RA   Khan T., Li J., Fellay J., Roussel L., Shahrooei M., Alosaimi M.F.,
RA   Mansouri D., Al-Saud H., Al-Mulla F., Almourfi F., Al-Muhsen S.Z.,
RA   Alsohime F., Al Turki S., Hasanato R., van de Beek D., Biondi A.,
RA   Bettini L.R., D'Angio' M., Bonfanti P., Imberti L., Sottini A., Paghera S.,
RA   Quiros-Roldan E., Rossi C., Oler A.J., Tompkins M.F., Alba C.,
RA   Vandernoot I., Goffard J.C., Smits G., Migeotte I., Haerynck F.,
RA   Soler-Palacin P., Martin-Nalda A., Colobran R., Morange P.E., Keles S.,
RA   Coelkesen F., Ozcelik T., Yasar K.K., Senoglu S., Karabela S.N.,
RA   Rodriguez-Gallego C., Novelli G., Hraiech S., Tandjaoui-Lambiotte Y.,
RA   Duval X., Laouenan C., Snow A.L., Dalgard C.L., Milner J.D., Vinh D.C.,
RA   Mogensen T.H., Marr N., Spaan A.N., Boisson B., Boisson-Dupuis S.,
RA   Bustamante J., Puel A., Ciancanelli M.J., Meyts I., Maniatis T.,
RA   Soumelis V., Amara A., Nussenzweig M., Garcia-Sastre A., Krammer F.,
RA   Pujol A., Duffy D., Lifton R.P., Zhang S.Y., Gorochov G., Beziat V.,
RA   Jouanguy E., Sancho-Shimizu V., Rice C.M., Abel L., Notarangelo L.D.,
RA   Cobat A., Su H.C., Casanova J.L.;
RT   "Inborn errors of type I IFN immunity in patients with life-threatening
RT   COVID-19.";
RL   Science 370:0-0(2020).
CC   -!- FUNCTION: Involved in innate immunity against invading pathogens.
CC       Adapter used by TLR3, TLR4 (through TICAM2) and TLR5 to mediate NF-
CC       kappa-B and interferon-regulatory factor (IRF) activation, and to
CC       induce apoptosis (PubMed:12471095, PubMed:12539043, PubMed:14739303,
CC       PubMed:28747347). Ligand binding to these receptors results in TRIF
CC       recruitment through its TIR domain (PubMed:12471095, PubMed:12539043,
CC       PubMed:14739303). Distinct protein-interaction motifs allow recruitment
CC       of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to
CC       the activation of transcription factors IRF3 and IRF7, NF-kappa-B and
CC       FADD respectively (PubMed:12471095, PubMed:12539043, PubMed:14739303).
CC       Phosphorylation by TBK1 on the pLxIS motif leads to recruitment and
CC       subsequent activation of the transcription factor IRF3 to induce
CC       expression of type I interferon and exert a potent immunity against
CC       invading pathogens (PubMed:25636800). Component of a multi-helicase-
CC       TICAM1 complex that acts as a cytoplasmic sensor of viral double-
CC       stranded RNA (dsRNA) and plays a role in the activation of a cascade of
CC       antiviral responses including the induction of pro-inflammatory
CC       cytokines (By similarity). {ECO:0000250|UniProtKB:Q80UF7,
CC       ECO:0000269|PubMed:12471095, ECO:0000269|PubMed:12539043,
CC       ECO:0000269|PubMed:14739303, ECO:0000269|PubMed:25636800}.
CC   -!- SUBUNIT: Homodimer (PubMed:12539043). Found in a multi-helicase-TICAM1
CC       complex at least composed of DHX36, DDX1, DDX21 and TICAM1; this
CC       complex exists in resting cells with or without poly(I:C) RNA ligand
CC       stimulation. Interacts (via TIR domain) with DDX21 (via C-terminus).
CC       Interacts (via TIR domain) with DHX36 (via C-terminus) (By similarity).
CC       Interacts with AZI2 and IRF7 (PubMed:12471095, PubMed:15611223).
CC       Interacts with TICAM2 in TLR4 recruitment (PubMed:12721283,
CC       PubMed:25736436). Interaction with PIAS4 inhibits the TICAM1-induced
CC       NF-kappa-B, IRF and IFNB1 activation (PubMed:15251447). Interacts with
CC       IKBKB and IKBKE. Interaction with SARM1 blocks TICAM1-dependent
CC       transcription factor activation (PubMed:16964262). Interacts with TRAF3
CC       (By similarity). Interacts (when phosphorylated) with IRF3; following
CC       activation and phosphorylation on the pLxIS motif by TBK1, recruits
CC       IRF3 (PubMed:12471095, PubMed:14739303, PubMed:25636800,
CC       PubMed:27302953). Interacts with TBK1, TRAF6 and RIPK1 and these
CC       interactions are enhanced in the presence of WDFY1 (PubMed:14982987,
CC       PubMed:25736436). Interacts with TRAFD1 (By similarity). Interacts with
CC       UBQLN1 (via UBA domain) (PubMed:21695056). Interacts with TLR4 in
CC       response to LPS in a WDFY1-dependent manner (By similarity). Interacts
CC       with WDFY1 in response to poly(I:C) (By similarity). Interacts (via the
CC       TIR domain) with TLR3 in response to poly(I:C) and this interaction is
CC       enhanced in the presence of WDFY1 (PubMed:25736436). Interacts with
CC       TRIM56 (PubMed:22948160). Component of a multi-helicase-TICAM1 complex
CC       that acts as a cytoplasmic sensor of viral double-stranded RNA (dsRNA)
CC       and plays a role in the activation of a cascade of antiviral responses
CC       including the induction of pro-inflammatory cytokines (By similarity).
CC       Interacts (via the TIR domain) with TLR5 (PubMed:20855887). Interacts
CC       with TRIM8 (PubMed:28747347). {ECO:0000250|UniProtKB:Q80UF7,
CC       ECO:0000269|PubMed:12471095, ECO:0000269|PubMed:12539043,
CC       ECO:0000269|PubMed:12721283, ECO:0000269|PubMed:14739303,
CC       ECO:0000269|PubMed:14982987, ECO:0000269|PubMed:15251447,
CC       ECO:0000269|PubMed:15611223, ECO:0000269|PubMed:16964262,
CC       ECO:0000269|PubMed:20855887, ECO:0000269|PubMed:21695056,
CC       ECO:0000269|PubMed:22948160, ECO:0000269|PubMed:25636800,
CC       ECO:0000269|PubMed:25736436, ECO:0000269|PubMed:27302953}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with hepatitis C virus (HCV)
CC       NS3/4A protease; this interaction leads to TICAM1 cleavage, thereby
CC       disrupting TLR3 signaling and preventing the establishment of an
CC       antiviral state. {ECO:0000269|PubMed:15710891}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Seneca Valley virus
CC       protease 3C; this interaction allows the cleavage of TICAM1/TRIF and
CC       subsequent suppression of host innate immunity.
CC       {ECO:0000269|PubMed:28566380}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via C-terminus) with
CC       coxsackievirus B3 (CVB3) protease 3C. {ECO:0000269|PubMed:21436888}.
CC   -!- INTERACTION:
CC       Q8IUC6; Q9UHD2: TBK1; NbExp=3; IntAct=EBI-525995, EBI-356402;
CC       Q8IUC6; Q9BRZ2: TRIM56; NbExp=2; IntAct=EBI-525995, EBI-1048636;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, autophagosome
CC       {ECO:0000269|PubMed:21695056}. Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q80UF7}. Mitochondrion
CC       {ECO:0000250|UniProtKB:Q80UF7}. Note=Colocalizes with UBQLN1 in the
CC       autophagosome (PubMed:21695056). Colocalizes in the cytosol with DDX1,
CC       DDX21 and DHX36. Colocalizes in the mitochondria with DDX1 and
CC       poly(I:C) RNA ligand. The multi-helicase-TICAM1 complex may translocate
CC       to the mitochondria upon poly(I:C) RNA ligand stimulation (By
CC       similarity). {ECO:0000250|UniProtKB:Q80UF7,
CC       ECO:0000269|PubMed:21695056}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed but with higher levels in
CC       liver. {ECO:0000269|PubMed:12471095, ECO:0000269|PubMed:12539043}.
CC   -!- DOMAIN: The pLxIS motif constitutes an IRF3-binding motif: following
CC       phosphorylation by TBK1, the phosphorylated pLxIS motif of TICAM1
CC       recruits IRF3 (PubMed:25636800). IRF3 is then phosphorylated and
CC       activated by TBK1 to induce type-I interferons and other cytokines
CC       (PubMed:25636800). {ECO:0000269|PubMed:25636800}.
CC   -!- DOMAIN: The N-terminal region is essential for activation of the IFNB
CC       promoter activity. {ECO:0000269|PubMed:12471095,
CC       ECO:0000269|PubMed:12539043, ECO:0000269|PubMed:14739303}.
CC   -!- DOMAIN: The N-terminal domain (TRIF-NTD) is globular and consists of
CC       two alpha-helical subdomains connected by a 14-residue linker. It
CC       shares structural similarity with IFIT family members N-terminal
CC       regions. {ECO:0000269|PubMed:24311583}.
CC   -!- PTM: Phosphorylated by TBK1 (PubMed:14530355, PubMed:25636800).
CC       Following activation, phosphorylated by TBK1 at Ser-210 in the pLxIS
CC       motif (PubMed:25636800). The phosphorylated pLxIS motif constitutes an
CC       IRF3-binding motif, leading to recruitment of the transcription factor
CC       IRF3 to induce type-I interferons and other cytokines (PubMed:25636800,
CC       PubMed:27302953). {ECO:0000269|PubMed:14530355,
CC       ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:27302953}.
CC   -!- PTM: Polyubiquitinated at Lys-229 by TRIM38 with 'Lys-48'-linked
CC       chains, leading to proteasomal degradation (PubMed:23056470).
CC       Polyubiquitinated with 'Lys-6'- and 'Lys-33'-linked chains in a TRIM8-
CC       dependent manner; ubiquitination disrupts the interaction with TBK1 and
CC       subsequent interferon production (PubMed:28747347).
CC       {ECO:0000269|PubMed:23056470, ECO:0000269|PubMed:28747347}.
CC   -!- PTM: (Microbial infection) Cleaved and degraded by hepatitis A virus
CC       (HAV) protein 3CD allowing the virus to disrupt host TLR3 signaling.
CC       {ECO:0000269|PubMed:21931545}.
CC   -!- PTM: (Microbial infection) Cleaved by CVB3 protease 3C allowing the
CC       virus to disrupt host TLR3 signaling. {ECO:0000269|PubMed:21436888}.
CC   -!- PTM: (Microbial infection) Cleaved by Seneca Valley virus protease 3C
CC       allowing the virus to disrupt host TLR3 signaling.
CC       {ECO:0000269|PubMed:28566380}.
CC   -!- PTM: (Microbial infection) Cleaved by protease 3C of human enterovirus
CC       D68 (EV68) allowing the virus to disrupt host TLR3 signaling.
CC       {ECO:0000269|PubMed:24672048}.
CC   -!- PTM: (Microbial infection) Cleaved by HCV protease NS3/4A, thereby
CC       disrupting TLR3 signaling and preventing the establishment of an
CC       antiviral state. {ECO:0000269|PubMed:15710891}.
CC   -!- DISEASE: Encephalopathy, acute, infection-induced, 6, herpes-specific
CC       (IIAE6) [MIM:614850]: A rare complication of human herpesvirus 1 (HHV-
CC       1) infection, occurring in only a small minority of HHV-1 infected
CC       individuals. It is characterized by hemorrhagic necrosis of parts of
CC       the temporal and frontal lobes. Onset is over several days and involves
CC       fever, headache, seizures, stupor, and often coma, frequently with a
CC       fatal outcome. {ECO:0000269|PubMed:22105173}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAO85488.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB093555; BAC44839.1; -; mRNA.
DR   EMBL; AB086380; BAC55579.1; -; mRNA.
DR   EMBL; AB446484; BAG55261.1; -; mRNA.
DR   EMBL; AB097023; BAC77376.1; -; mRNA.
DR   EMBL; BC009860; AAH09860.2; -; mRNA.
DR   EMBL; BC136556; AAI36557.1; -; mRNA.
DR   EMBL; BC136557; AAI36558.1; -; mRNA.
DR   EMBL; AF492646; AAO85488.1; ALT_FRAME; mRNA.
DR   EMBL; AF070530; AAC28630.1; -; mRNA.
DR   CCDS; CCDS12136.1; -.
DR   RefSeq; NP_891549.1; NM_182919.3.
DR   PDB; 2M1X; NMR; -; A=387-545.
DR   PDB; 2M63; NMR; -; A=1-156.
DR   PDB; 3RC4; X-ray; 1.50 A; B=360-372.
DR   PDB; 4BSX; X-ray; 2.23 A; A/B/C/D=1-153.
DR   PDB; 4C0M; X-ray; 2.80 A; A/B/C/D=1-153.
DR   PDB; 5JEL; X-ray; 1.60 A; B=199-217.
DR   PDBsum; 2M1X; -.
DR   PDBsum; 2M63; -.
DR   PDBsum; 3RC4; -.
DR   PDBsum; 4BSX; -.
DR   PDBsum; 4C0M; -.
DR   PDBsum; 5JEL; -.
DR   AlphaFoldDB; Q8IUC6; -.
DR   BMRB; Q8IUC6; -.
DR   SMR; Q8IUC6; -.
DR   BioGRID; 127114; 50.
DR   CORUM; Q8IUC6; -.
DR   DIP; DIP-33490N; -.
DR   IntAct; Q8IUC6; 13.
DR   MINT; Q8IUC6; -.
DR   STRING; 9606.ENSP00000248244; -.
DR   iPTMnet; Q8IUC6; -.
DR   PhosphoSitePlus; Q8IUC6; -.
DR   BioMuta; TICAM1; -.
DR   DMDM; 74727957; -.
DR   EPD; Q8IUC6; -.
DR   jPOST; Q8IUC6; -.
DR   MassIVE; Q8IUC6; -.
DR   MaxQB; Q8IUC6; -.
DR   PaxDb; Q8IUC6; -.
DR   PeptideAtlas; Q8IUC6; -.
DR   ProteomicsDB; 70544; -.
DR   Antibodypedia; 11536; 402 antibodies from 42 providers.
DR   DNASU; 148022; -.
DR   Ensembl; ENST00000248244.6; ENSP00000248244.4; ENSG00000127666.11.
DR   GeneID; 148022; -.
DR   KEGG; hsa:148022; -.
DR   MANE-Select; ENST00000248244.6; ENSP00000248244.4; NM_182919.4; NP_891549.1.
DR   UCSC; uc002mbi.5; human.
DR   AGR; HGNC:18348; -.
DR   CTD; 148022; -.
DR   DisGeNET; 148022; -.
DR   GeneCards; TICAM1; -.
DR   HGNC; HGNC:18348; TICAM1.
DR   HPA; ENSG00000127666; Tissue enhanced (esophagus).
DR   MalaCards; TICAM1; -.
DR   MIM; 607601; gene.
DR   MIM; 614850; phenotype.
DR   neXtProt; NX_Q8IUC6; -.
DR   OpenTargets; ENSG00000127666; -.
DR   Orphanet; 1930; Herpes simplex virus encephalitis.
DR   PharmGKB; PA142670812; -.
DR   VEuPathDB; HostDB:ENSG00000127666; -.
DR   eggNOG; ENOG502RXF3; Eukaryota.
DR   GeneTree; ENSGT00940000162411; -.
DR   HOGENOM; CLU_022539_0_0_1; -.
DR   InParanoid; Q8IUC6; -.
DR   OMA; TRHGWQD; -.
DR   OrthoDB; 4640439at2759; -.
DR   PhylomeDB; Q8IUC6; -.
DR   TreeFam; TF336953; -.
DR   PathwayCommons; Q8IUC6; -.
DR   Reactome; R-HSA-140534; Caspase activation via Death Receptors in the presence of ligand.
DR   Reactome; R-HSA-166166; MyD88-independent TLR4 cascade.
DR   Reactome; R-HSA-168164; Toll Like Receptor 3 (TLR3) Cascade.
DR   Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-2562578; TRIF-mediated programmed cell death.
DR   Reactome; R-HSA-5602566; TICAM1 deficiency - HSE.
DR   Reactome; R-HSA-5602571; TRAF3 deficiency - HSE.
DR   Reactome; R-HSA-9013957; TLR3-mediated TICAM1-dependent programmed cell death.
DR   Reactome; R-HSA-9013973; TICAM1-dependent activation of IRF3/IRF7.
DR   Reactome; R-HSA-9014325; TICAM1,TRAF6-dependent induction of TAK1 complex.
DR   Reactome; R-HSA-936964; Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-HSA-937072; TRAF6-mediated induction of TAK1 complex within TLR4 complex.
DR   Reactome; R-HSA-975163; IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation.
DR   SignaLink; Q8IUC6; -.
DR   SIGNOR; Q8IUC6; -.
DR   BioGRID-ORCS; 148022; 16 hits in 1159 CRISPR screens.
DR   ChiTaRS; TICAM1; human.
DR   EvolutionaryTrace; Q8IUC6; -.
DR   GenomeRNAi; 148022; -.
DR   Pharos; Q8IUC6; Tbio.
DR   PRO; PR:Q8IUC6; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q8IUC6; protein.
DR   Bgee; ENSG00000127666; Expressed in lower esophagus mucosa and 152 other tissues.
DR   ExpressionAtlas; Q8IUC6; baseline and differential.
DR   Genevisible; Q8IUC6; HS.
DR   GO; GO:0005776; C:autophagosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; IDA:UniProt.
DR   GO; GO:0005768; C:endosome; IDA:UniProt.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0097342; C:ripoptosome; IDA:UniProtKB.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:UniProt.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0097027; F:ubiquitin-protein transferase activator activity; IDA:UniProt.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0042100; P:B cell proliferation; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; ISS:ARUK-UCL.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0002281; P:macrophage activation involved in immune response; IEA:Ensembl.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IEA:Ensembl.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; ISS:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IEA:Ensembl.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; IEA:Ensembl.
DR   GO; GO:0002735; P:positive regulation of myeloid dendritic cell cytokine production; ISS:UniProtKB.
DR   GO; GO:0032816; P:positive regulation of natural killer cell activation; IBA:GO_Central.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IBA:GO_Central.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032092; P:positive regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IDA:UniProt.
DR   GO; GO:0043254; P:regulation of protein-containing complex assembly; IEA:Ensembl.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IMP:MGI.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; IDA:UniProt.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; IMP:CACAO.
DR   Gene3D; 1.25.40.780; -; 1.
DR   Gene3D; 3.40.50.10140; Toll/interleukin-1 receptor homology (TIR) domain; 1.
DR   InterPro; IPR025735; RHIM_dom.
DR   InterPro; IPR046946; TCAM1/2.
DR   InterPro; IPR017278; TICAM1.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR   InterPro; IPR040886; TRIF_N.
DR   PANTHER; PTHR47230; TIR DOMAIN-CONTAINING ADAPTER MOLECULE 1; 1.
DR   PANTHER; PTHR47230:SF1; TIR DOMAIN-CONTAINING ADAPTER MOLECULE 1; 1.
DR   Pfam; PF12721; RHIM; 1.
DR   Pfam; PF17798; TRIF-NTD; 1.
DR   PIRSF; PIRSF037744; TIR_Ticam; 1.
DR   SUPFAM; SSF52200; Toll/Interleukin receptor TIR domain; 1.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antiviral defense; Apoptosis; Cytoplasm; Cytoplasmic vesicle;
KW   Disease variant; Host-virus interaction; Immunity; Inflammatory response;
KW   Innate immunity; Isopeptide bond; Mitochondrion; Phosphoprotein;
KW   Reference proteome; Ubl conjugation.
FT   CHAIN           1..712
FT                   /note="TIR domain-containing adapter molecule 1"
FT                   /id="PRO_0000317663"
FT   DOMAIN          393..553
FT                   /note="TIR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT   REGION          1..153
FT                   /note="TRIF-NTD"
FT                   /evidence="ECO:0000269|PubMed:24311583"
FT   REGION          216..316
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          336..384
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          512..712
FT                   /note="Sufficient to induce apoptosis"
FT   REGION          620..677
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           84..91
FT                   /note="TRAF6-binding"
FT   MOTIF           207..210
FT                   /note="pLxIS motif"
FT                   /evidence="ECO:0000269|PubMed:25636800"
FT   MOTIF           248..255
FT                   /note="TRAF6-binding"
FT   MOTIF           299..309
FT                   /note="TRAF6-binding"
FT   COMPBIAS        261..278
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        289..306
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        346..372
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        620..675
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            148
FT                   /note="(Microbial infection) Cleavage by CV3B"
FT                   /evidence="ECO:0000269|PubMed:21436888"
FT   SITE            159..160
FT                   /note="(Microbial infection) Cleavage; by viral Seneca
FT                   Valley virus protease 3C"
FT                   /evidence="ECO:0000269|PubMed:28566380"
FT   SITE            190
FT                   /note="(Microbial infection) Cleavage; by viral HAV 3CD"
FT                   /evidence="ECO:0000269|PubMed:21931545"
FT   SITE            312..313
FT                   /note="(Microbial infection) Cleavage; by viral EV68
FT                   protease C"
FT                   /evidence="ECO:0000269|PubMed:24672048"
FT   SITE            372..373
FT                   /note="(Microbial infection) Cleavage; by viral HCV NS3/4A"
FT                   /evidence="ECO:0000269|PubMed:15710891"
FT   SITE            554
FT                   /note="(Microbial infection) Cleavage; by viral HAV 3CD"
FT                   /evidence="ECO:0000269|PubMed:21931545"
FT   SITE            653..654
FT                   /note="(Microbial infection) Cleavage; by viral EV68
FT                   protease C"
FT                   /evidence="ECO:0000269|PubMed:24672048"
FT   MOD_RES         210
FT                   /note="Phosphoserine; by TBK1"
FT                   /evidence="ECO:0000269|PubMed:25636800,
FT                   ECO:0000269|PubMed:27302953"
FT   CROSSLNK        229
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q80UF7"
FT   VARIANT         4
FT                   /note="T -> I (inhibition of IFNB induction;
FT                   dbSNP:rs114566317)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084053"
FT   VARIANT         46
FT                   /note="M -> I (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_038789"
FT   VARIANT         60
FT                   /note="S -> C (inhibition of IFNB induction;
FT                   dbSNP:rs201782115)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084054"
FT   VARIANT         71
FT                   /note="R -> Q (no effect on IFNB induction;
FT                   dbSNP:rs372818181)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084055"
FT   VARIANT         75
FT                   /note="R -> C (in dbSNP:rs11466719)"
FT                   /id="VAR_051416"
FT   VARIANT         80
FT                   /note="V -> M (no effect on IFNB induction;
FT                   dbSNP:rs199816697)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084056"
FT   VARIANT         111
FT                   /note="A -> T (no effect on IFNB induction;
FT                   dbSNP:rs201291933)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084057"
FT   VARIANT         141
FT                   /note="Missing (inhibition of IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084058"
FT   VARIANT         157
FT                   /note="T -> M (no effect on IFNB induction;
FT                   dbSNP:rs770166865)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084059"
FT   VARIANT         186
FT                   /note="S -> L (in IIAE6; no effect on IFNB induction;
FT                   dbSNP:rs146550489)"
FT                   /evidence="ECO:0000269|PubMed:22105173,
FT                   ECO:0000269|PubMed:32972995"
FT                   /id="VAR_069082"
FT   VARIANT         275
FT                   /note="L -> V (in dbSNP:rs11466721)"
FT                   /id="VAR_051417"
FT   VARIANT         302
FT                   /note="V -> L (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084060"
FT   VARIANT         377
FT                   /note="T -> I (no effect on IFNB induction;
FT                   dbSNP:rs147816959)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084061"
FT   VARIANT         386
FT                   /note="L -> P (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084062"
FT   VARIANT         392
FT                   /note="Q -> K (inhibition of IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084063"
FT   VARIANT         465
FT                   /note="S -> N (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084064"
FT   VARIANT         557
FT                   /note="D -> N (no effect on IFNB induction;
FT                   dbSNP:rs143066432)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084065"
FT   VARIANT         595
FT                   /note="M -> L (no effect on IFNB induction;
FT                   dbSNP:rs561021962)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084066"
FT   VARIANT         598
FT                   /note="G -> W (no effect on IFNB induction;
FT                   dbSNP:rs150224968)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084067"
FT   VARIANT         666
FT                   /note="A -> T (in dbSNP:rs11466724)"
FT                   /id="VAR_051418"
FT   VARIANT         702
FT                   /note="Q -> R (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084068"
FT   MUTAGEN         88
FT                   /note="E->A: Reduces binding to TRAF6 and activation of
FT                   NFKB signaling pathway; when associated with A-252 and
FT                   A-303."
FT                   /evidence="ECO:0000269|PubMed:14530355"
FT   MUTAGEN         159
FT                   /note="Q->A: Complete loss of cleavage by Seneca Valley
FT                   virus protease 3C."
FT                   /evidence="ECO:0000269|PubMed:28566380"
FT   MUTAGEN         190
FT                   /note="Q->A: No effect on cleavage by Seneca Valley virus
FT                   protease 3C."
FT                   /evidence="ECO:0000269|PubMed:28566380"
FT   MUTAGEN         190
FT                   /note="Q->R: No cleavage by HAV 3CD."
FT                   /evidence="ECO:0000269|PubMed:21931545"
FT   MUTAGEN         202
FT                   /note="S->A: Decreased interaction with IRF3."
FT                   /evidence="ECO:0000269|PubMed:27302953"
FT   MUTAGEN         210..214
FT                   /note="SQSPT->AQAPA: Abolished ability to activate IRF3."
FT                   /evidence="ECO:0000269|PubMed:25636800"
FT   MUTAGEN         210
FT                   /note="S->A: Abolished interaction with IRF3."
FT                   /evidence="ECO:0000269|PubMed:27302953"
FT   MUTAGEN         252
FT                   /note="E->A: Loss of TCAM1-induced NF-kappa-B activation.
FT                   Reduces interaction with TRAF6 and activation of NF-kappa-B
FT                   signaling pathway; when associated with A-88 and A-303."
FT                   /evidence="ECO:0000269|PubMed:14530355,
FT                   ECO:0000269|PubMed:14982987"
FT   MUTAGEN         281
FT                   /note="D->E: Resistant to caspase cleavage, no effect on
FT                   TRIM38-mediated degradation; when associated with E-289."
FT                   /evidence="ECO:0000269|PubMed:23056470"
FT   MUTAGEN         289
FT                   /note="D->E: Resistant to caspase cleavage, no effect on
FT                   TRIM38-mediated degradation; when associated with E-281."
FT                   /evidence="ECO:0000269|PubMed:23056470"
FT   MUTAGEN         303
FT                   /note="E->A: Reduces binding to TRAF6 and activation of
FT                   NFKB signaling pathway; when associated with A-88 and
FT                   A-252."
FT                   /evidence="ECO:0000269|PubMed:14530355"
FT   MUTAGEN         372
FT                   /note="C->R: Complete loss of cleavage by HCVNS3/4A
FT                   protease."
FT                   /evidence="ECO:0000269|PubMed:15710891"
FT   MUTAGEN         434
FT                   /note="P->H: Abolishes interaction with TLR3."
FT                   /evidence="ECO:0000269|PubMed:12539043"
FT   MUTAGEN         493
FT                   /note="E->A: Loss of TCAM1-induced NF-kappa-B and IRF3
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:14982987"
FT   MUTAGEN         554
FT                   /note="Q->R: No cleavage by HAV 3CD."
FT                   /evidence="ECO:0000269|PubMed:21931545"
FT   MUTAGEN         653
FT                   /note="Q->A: Complete loss of cleavage by CV3B; when
FT                   associated with A-659; A-671 and A-702."
FT                   /evidence="ECO:0000269|PubMed:21436888"
FT   MUTAGEN         659
FT                   /note="Q->A: Complete loss of cleavage by CV3B; when
FT                   associated with A-653; A-671 and A-702."
FT                   /evidence="ECO:0000269|PubMed:21436888"
FT   MUTAGEN         672
FT                   /note="Q->A: Complete loss of cleavage by CV3B; when
FT                   associated with A-653; A-659 and A-702."
FT                   /evidence="ECO:0000269|PubMed:21436888"
FT   MUTAGEN         702
FT                   /note="Q->A: Complete loss of cleavage by CV3B; when
FT                   associated with A-653; A-659 and A-671."
FT                   /evidence="ECO:0000269|PubMed:21436888"
FT   CONFLICT        147
FT                   /note="D -> T (in Ref. 6; AAO85488)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        150
FT                   /note="G -> W (in Ref. 6; AAO85488)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        162
FT                   /note="L -> S (in Ref. 6; AAO85488)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        633..659
FT                   /note="Missing (in Ref. 6; AAO85488)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        660
FT                   /note="S -> P (in Ref. 6; AAO85488)"
FT                   /evidence="ECO:0000305"
FT   HELIX           8..16
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   HELIX           20..30
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   HELIX           40..50
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   HELIX           54..62
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   TURN            63..66
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   HELIX           68..76
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   STRAND          83..85
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   HELIX           93..105
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   HELIX           111..127
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   HELIX           133..144
FT                   /evidence="ECO:0007829|PDB:4BSX"
FT   HELIX           200..206
FT                   /evidence="ECO:0007829|PDB:5JEL"
FT   STRAND          369..371
FT                   /evidence="ECO:0007829|PDB:3RC4"
FT   HELIX           406..417
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   STRAND          431..433
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   HELIX           444..447
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   STRAND          448..455
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   HELIX           462..475
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   TURN            477..480
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   STRAND          486..490
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   STRAND          492..494
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   HELIX           503..506
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   STRAND          508..510
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   STRAND          513..516
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   HELIX           520..527
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   HELIX           530..535
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   TURN            536..540
FT                   /evidence="ECO:0007829|PDB:2M1X"
FT   HELIX           541..543
FT                   /evidence="ECO:0007829|PDB:2M1X"
SQ   SEQUENCE   712 AA;  76422 MW;  5D071E3BE9240D9A CRC64;
     MACTGPSLPS AFDILGAAGQ DKLLYLKHKL KTPRPGCQGQ DLLHAMVLLK LGQETEARIS
     LEALKADAVA RLVARQWAGV DSTEDPEEPP DVSWAVARLY HLLAEEKLCP ASLRDVAYQE
     AVRTLSSRDD HRLGELQDEA RNRCGWDIAG DPGSIRTLQS NLGCLPPSSA LPSGTRSLPR
     PIDGVSDWSQ GCSLRSTGSP ASLASNLEIS QSPTMPFLSL HRSPHGPSKL CDDPQASLVP
     EPVPGGCQEP EEMSWPPSGE IASPPELPSS PPPGLPEVAP DATSTGLPDT PAAPETSTNY
     PVECTEGSAG PQSLPLPILE PVKNPCSVKD QTPLQLSVED TTSPNTKPCP PTPTTPETSP
     PPPPPPPSST PCSAHLTPSS LFPSSLESSS EQKFYNFVIL HARADEHIAL RVREKLEALG
     VPDGATFCED FQVPGRGELS CLQDAIDHSA FIILLLTSNF DCRLSLHQVN QAMMSNLTRQ
     GSPDCVIPFL PLESSPAQLS SDTASLLSGL VRLDEHSQIF ARKVANTFKP HRLQARKAMW
     RKEQDTRALR EQSQHLDGER MQAAALNAAY SAYLQSYLSY QAQMEQLQVA FGSHMSFGTG
     APYGARMPFG GQVPLGAPPP FPTWPGCPQP PPLHAWQAGT PPPPSPQPAA FPQSLPFPQS
     PAFPTASPAP PQSPGLQPLI IHHAQMVQLG LNNHMWNQRG SQAPEDKTQE AE
//
